QS Investors LLC held its stake in Chimerix, Inc. (NASDAQ:CMRX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 226,678 shares of the biopharmaceutical company’s stock at the end of the second quarter. QS Investors LLC owned approximately 0.48% of Chimerix worth $1,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of CMRX. Redmile Group LLC boosted its stake in Chimerix by 29.3% during the 1st quarter. Redmile Group LLC now owns 4,325,055 shares of the biopharmaceutical company’s stock valued at $27,594,000 after purchasing an additional 979,096 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Chimerix by 114.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after purchasing an additional 557,927 shares in the last quarter. Morgan Stanley boosted its stake in Chimerix by 203.9% during the 1st quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock valued at $3,944,000 after purchasing an additional 414,717 shares in the last quarter. Renaissance Technologies LLC bought a new position in Chimerix during the 1st quarter valued at $1,975,000. Finally, Vanguard Group Inc. boosted its stake in Chimerix by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,848,257 shares of the biopharmaceutical company’s stock valued at $11,792,000 after purchasing an additional 213,894 shares in the last quarter. 67.53% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have issued reports on CMRX. ValuEngine lowered Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday, August 9th.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/10/12/qs-investors-llc-holds-holdings-in-chimerix-inc-cmrx.html.
Shares of Chimerix, Inc. (NASDAQ CMRX) opened at 5.37 on Thursday. Chimerix, Inc. has a 1-year low of $3.66 and a 1-year high of $6.64. The company’s market capitalization is $252.64 million. The stock’s 50 day moving average price is $5.00 and its 200 day moving average price is $5.15.
Chimerix (NASDAQ:CMRX) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. The firm had revenue of $0.68 million during the quarter, compared to analyst estimates of $1.28 million. Analysts expect that Chimerix, Inc. will post ($1.63) EPS for the current year.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.